Research
Cellular
Baseline disease severity, depressive symptoms, insulin resistance, and preperitoneal fat were negatively associated with PASI improvement.
Understanding these associations can help tailor treatment strategies for better outcomes.
GoodSupportsmedium confidence
Baseline disease severity, depressive symptoms, insulin resistance and preperitoneal fat were negatively associated with PASI improvement.
Why this rating
The study is a prospective cohort study.
Source
Dermatological and metabolic benefits of semaglutide in psoriasis with obesity: a 6-month prospective cohort study
Joana Nicolau et al. · Clinical and Experimental Dermatology · 2025
DOI 10.1093/ced/llaf473
cohort · n=43Cited 4×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- After 6 months of semaglutide treatment, participants showed significant reductions in Psoriasis Area and Severity Index (PASI) by 48%, body mass index (BMI), and preperitoneal and superficial fat.Good
- Semaglutide treatment is associated with improvements in quality of life (DLQI) and depressive symptoms (BDI) after 6 months.Good
Related findings · Cellular
- Athletes aiming to reduce fat mass and preserve FFM should consume protein intakes in the range of ∼1.8-2.7 g kg(-1) d(-1).Strong
- A minimum daily protein intake of ≥1.6 g/kg is necessary to observe significant improvements in muscle mass from whey protein supplementation.Strong
- Most athletes ideally need 1.2 to 2.0 grams/kg of body weight/day of protein, preferably split across 3-4 meals.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →